Shoppers Foundation for Women's Health highlights the most pressing disparities faced by women across Canada
New research from Shoppers Drug Mart's charitable arm reveals sizeable gaps in education, awareness for common menstrual health conditions.
New research from Shoppers Drug Mart's charitable arm reveals sizeable gaps in education, awareness for common menstrual health conditions.
KeySource announces changes to leadership team.
In pivotal Phase 3 trials, TRYPTYR demonstrated rapid natural tear production as early as Day 1
New law safeguards pharmacies and expands patient access.
New online badging across thousands of eligible products makes it easier for customers to shop with their health plan.
The findings reflect broader industry pressures, as plans respond to rising expectations around cost transparency, digital access and personalized service.
The topical formulation is now accessible in all 50 states following a consultation with a licensed medical provider via Eden's telehealth platform.
As part of the action, CMS is ramping up financial oversight across the board to identify and stop improper spending.
The move, announced Tuesday on X, appears to effectively shortcut a process set up by the agency's outside advisers to discuss and make changes to the CDC's influential vaccination guidance.
Bundled offer includes Wegovy at $199 and LifeMD’s Virtual Weight Loss Program for a total first-month cost of $299, $599 per month thereafter.
Codrean was appointed by the board of directors and took over as president on June 1st.
GoodRx is hosting a webinar on June 3 and 4 to discuss how the company is supporting direct contracting with GoodRx.
By centralizing prescription processing, Walmart aims to free up in-store pharmacists to focus on patient care and clinical services.
New AI-powered copilot automates clinical and administrative tasks.
Dr. Creagh Milford has been with CVS since 2021, most recently serving as president of retail health. He will serve as president of Oak Street Health on an interim basis.
Airsupra demonstrated a 47% reduction in the risk of severe exacerbations in mild asthma compared with albuterol alone.